These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 12089585)

  • 21. Biotechnology. Mixed reactions to merger.
    Gershon D
    Nature; 1990 Feb; 343(6260):681. PubMed ID: 2304541
    [No Abstract]   [Full Text] [Related]  

  • 22. Partnering challenges for startups.
    French JM
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE40-2. PubMed ID: 12089586
    [No Abstract]   [Full Text] [Related]  

  • 23. Should platform companies move toward products?
    Ratner M
    Nat Biotechnol; 1999 Jan; 17(1):16-7. PubMed ID: 9920255
    [No Abstract]   [Full Text] [Related]  

  • 24. NIH licensing performance under par.
    Garber K
    Nat Biotechnol; 2004 Dec; 22(12):1607-8. PubMed ID: 15605428
    [No Abstract]   [Full Text] [Related]  

  • 25. The commercialization of biotechnology: important aspects of technology licensing.
    Irvine S
    Aust J Biotechnol; 1991 Apr; 5(2):105-8. PubMed ID: 1367321
    [No Abstract]   [Full Text] [Related]  

  • 26. [Patent rights and the free research. The boundary between basic research and private sector is not longer razor-sharp].
    Westerlund L
    Lakartidningen; 2005 Sep 26-Oct 2; 102(39):2737. PubMed ID: 16245544
    [No Abstract]   [Full Text] [Related]  

  • 27. Tech transfer revs up.
    Lawrence S
    Nat Biotechnol; 2006 Jan; 24(1):13. PubMed ID: 16404380
    [No Abstract]   [Full Text] [Related]  

  • 28. Calculating the value & risk in licensing deals. 20-21 November 2002, Brussels, Belgium.
    Contrafouris Y
    IDrugs; 2003 Jan; 6(1):21-2. PubMed ID: 12838965
    [No Abstract]   [Full Text] [Related]  

  • 29. Syndication--value in numbers.
    Sanborn KT
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE54-6. PubMed ID: 12089590
    [No Abstract]   [Full Text] [Related]  

  • 30. Asia calls for united approach to commerce.
    Saegusa A
    Nat Biotechnol; 1999 Oct; 17(10):946-7. PubMed ID: 10504685
    [No Abstract]   [Full Text] [Related]  

  • 31. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 32. Making it in the biotech business.
    Gewin V
    Nature; 2005 May; 435(7038):124-5. PubMed ID: 15875029
    [No Abstract]   [Full Text] [Related]  

  • 33. Changing partners.
    Nat Biotechnol; 2002 Sep; 20(9):855. PubMed ID: 12205487
    [No Abstract]   [Full Text] [Related]  

  • 34. When times get tough.
    Jong S
    Nat Biotechnol; 2009 Mar; 27(3):226-8. PubMed ID: 19274868
    [No Abstract]   [Full Text] [Related]  

  • 35. A counselor's dose of preventive medicine.
    Redlick D; Kapner V
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE51-3. PubMed ID: 12089589
    [No Abstract]   [Full Text] [Related]  

  • 36. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 37. Biotech's new colossus. Move over, Big Pharma. Amgen boasts better growth.
    Stipp D
    Fortune; 2002 Apr; 145(8):144-6, 148, 150. PubMed ID: 11961884
    [No Abstract]   [Full Text] [Related]  

  • 38. Innovation in Manchester.
    Smith M
    Nat Biotechnol; 2002 Jul; 20 Suppl():BE24-6. PubMed ID: 12089581
    [No Abstract]   [Full Text] [Related]  

  • 39. Selection of licensing candidates in the pharmaceutical industry: an application of the analytic hierarchy process.
    Ross ME; Nydick RL
    J Health Care Mark; 1992 Jun; 12(2):60-5. PubMed ID: 10119215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The economics of licensing contracts.
    Mason R; Savva N; Scholtes S
    Nat Biotechnol; 2008 Aug; 26(8):855-7. PubMed ID: 18700253
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.